Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(2021) In EMBO Molecular Medicine 13(8).- Abstract
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([18F]RO948 in BioFINDER-2, [18F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau... (More)
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([18F]RO948 in BioFINDER-2, [18F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEɛ4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ-pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2021-08-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, CSF, PET, plasma, tau
- in
- EMBO Molecular Medicine
- volume
- 13
- issue
- 8
- article number
- e14398
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:34254442
- scopus:85111722211
- ISSN
- 1757-4676
- DOI
- 10.15252/emmm.202114398
- language
- English
- LU publication?
- yes
- id
- 57de1938-6974-44e8-be6c-89f3066b14fd
- date added to LUP
- 2021-08-30 15:13:56
- date last changed
- 2024-06-16 17:55:07
@article{57de1938-6974-44e8-be6c-89f3066b14fd, abstract = {{<p>PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([<sup>18</sup>F]RO948 in BioFINDER-2, [<sup>18</sup>F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEɛ4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ-pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.</p>}}, author = {{Ossenkoppele, Rik and Reimand, Juhan and Smith, Ruben and Leuzy, Antoine and Strandberg, Olof and Palmqvist, Sebastian and Stomrud, Erik and Zetterberg, Henrik and Scheltens, Philip and Dage, Jeffrey L. and Bouwman, Femke and Blennow, Kaj and Mattsson-Carlgren, Niklas and Janelidze, Shorena and Hansson, Oskar}}, issn = {{1757-4676}}, keywords = {{Alzheimer's disease; CSF; PET; plasma; tau}}, language = {{eng}}, month = {{08}}, number = {{8}}, publisher = {{Wiley-Blackwell}}, series = {{EMBO Molecular Medicine}}, title = {{Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers}}, url = {{http://dx.doi.org/10.15252/emmm.202114398}}, doi = {{10.15252/emmm.202114398}}, volume = {{13}}, year = {{2021}}, }